Nutriband Inc.

NTRB

US67092M2089

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets 14:08:37 2024-06-04 EDT			5-day change	1st Jan Change
5.795 ^USD	-5.93%		+11.76%	+149.78%

05-31	Nutriband Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI
05-16	Nutriband Inc. Appoints Sergei Glinka to Its Board of Directors	CI

NUTRIBAND INC. : Financial Statements and Exhibits (form 8-K)

January 05, 2023 at 11:25 am

Item 9.01 Financial Statements and Exhibits





(d) Exhibits

The following exhibits are being filed with this Current Report on Form 8-K:





99.1       Nutriband Press Release dated January 5, 2023
104      Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       1

Latest news about Nutriband Inc.

Nutriband Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	05-31	CI
Nutriband Inc. Appoints Sergei Glinka to Its Board of Directors	05-16	CI
Tranche Update on Nutriband Inc.'s Equity Buyback Plan announced on December 30, 2021.	05-01	CI
Tranche Update on Nutriband Inc.'s Equity Buyback Plan announced on December 30, 2021.	05-01	CI
Tranche Update on Nutriband Inc.'s Equity Buyback Plan announced on December 30, 2021.	05-01	CI
Nutriband Inc. Reports Earnings Results for the Full Year Ended January 31, 2024	05-01	CI
Nutriband Inc. Closes $8.4 Million Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission	04-24	CI
Nutriband Inc. announced that it expects to receive $8.4 million in funding	04-22	CI
Nutriband Inc. Receives First Order from Fit for Life Group	04-01	CI
Nutriband Inc. Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch	03-27	CI
Nutriband Inc. Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented At 2024 American Academy of Pain Medicine Annual Meeting	03-25	CI
Nutriband Inc. Announces Data on the Incidence of Transdermal Patch Abuse and Accidental Pediatric Exposure Will Be Presented At the 2024 American Academy of Pain Medicine Annual Meeting	03-04	CI
Nutriband Signs Agreement With Kindeva Drug Delivery for Aversa Fentanyl	01-05	MT
Nutriband Inc. Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch	01-05	CI
Nutriband Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	12-13	CI
Nutriband Introduces Kinesiology Tape With Heating, Cooling Features	11-28	MT
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling	11-28	CI
Nutriband Signs Supplier Deal With KT Tape	11-08	MT
Nutriband Inc. Signs Supplier Agreement with KT Tape	11-08	CI
Top Premarket Decliners	11-07	MT
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-11	MT
Sector Update: Health Care	23-10-11	MT
Nutriband Says Buprenorphine Product Has Potential to Reach Up to $130 Million in Annual US Sales	23-10-11	MT
Nutriband Secures US Patent for Abuse Deterrent Transdermal Products	23-09-20	MT
Nutriband Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-11	CI

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-29 - Q2 2025 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
NUTRIBAND INC.	+149.78%	67.98M
ABBOTT LABORATORIES	-6.21%	179B
MEDTRONIC PLC	+0.80%	108B
BECTON, DICKINSON AND COMPANY	-2.03%	69.03B
DEXCOM, INC.	-6.32%	45.83B
CENCORA, INC.	+12.39%	45.39B
HOYA CORPORATION	+8.60%	43.17B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.88%	29.89B
TERUMO CORPORATION	+13.65%	25.49B
WEST PHARMACEUTICAL SERVICES, INC.	-8.87%	23.95B

Other Medical Equipment, Supplies & Distribution

Nutriband Inc.

Equities

NTRB

US67092M2089

Medical Equipment, Supplies & Distribution

NUTRIBAND INC. : Financial Statements and Exhibits (form 8-K)

Latest news about Nutriband Inc.

Chart Nutriband Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution